Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Johnson & Johnson
(NY:
JNJ
)
159.09
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Aug 15, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Johnson & Johnson
< Previous
1
2
...
24
25
26
27
28
29
30
31
32
...
99
100
Next >
What's Going On Pfizer's Subsidiary Biohaven Stock?
September 27, 2023
Pfizer Inc's (NYSE: PFE) subsidiary Biohaven Ltd (NYSE: BHVN) released an
Via
Benzinga
Why Immunovant Stock Is Bolting Higher Today
September 27, 2023
The company may have best-in-class autoimmune disease therapy under its roof.
Via
The Motley Fool
Biden's Urgent Action Against Antibiotic-Resistant Bacteria - Allocates $100M to Battle Deadly Superbugs
September 27, 2023
U.S. President Joe Biden is set to unveil a $100 million research initiative to tackle the growing threat of drug-resistant bacteria. More than a million people worldwide succumb to infections caused...
Via
Benzinga
Looking At Johnson & Johnson's Recent Unusual Options Activity
September 27, 2023
Via
Benzinga
3 Things About Johnson & Johnson That Smart Investors Know
September 27, 2023
J&J shares have missed out on the market rally so far this year.
Via
The Motley Fool
(JNJ) - Analyzing Johnson & Johnson's Short Interest
September 25, 2023
Via
Benzinga
Johnson & Johnson Unusual Options Activity
September 20, 2023
Via
Benzinga
Better Buy: J&J vs. Kenvue
September 13, 2023
You can count on both of these companies for passive income, too.
Via
The Motley Fool
2 Monster Stocks to Buy Without Any Hesitation
September 26, 2023
Recent bumps in the road won't deter these companies.
Via
The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
September 21, 2023
Via
Benzinga
2 Incredibly Cheap Dividend Stocks to Buy Now
September 20, 2023
High-quality dividend stocks are rarely cheap. These two names are an exception.
Via
The Motley Fool
Buying These 2 Stocks Is a Good Way to Hedge Against a Market Crash
September 20, 2023
Market crashes are inevitable, but certain stocks could limit potential damage.
Via
The Motley Fool
3 No-Brainer Stocks to Buy With $500 Right Now
September 20, 2023
A modest amount of money can go a long way when it's invested in industry-leading businesses.
Via
The Motley Fool
7 Safe and Steady Dividend Stocks to Buy for Volatile Time
September 19, 2023
Discover how these seven standout companies offer both security and growth potential in an uncertain financial landscape.
Via
InvestorPlace
Johnson & Johnson Unusual Options Activity
September 12, 2023
Via
Benzinga
3 High-Quality Dividend Stocks Yielding 3%-Plus to Buy for Decades of Rising Income
September 17, 2023
These companies generate durable and growing cash flows.
Via
The Motley Fool
3 Great Dividend Stocks You Can Buy for Less Than $50
September 15, 2023
These steady-Eddie operators are perfect bedrock stocks for investors despite trading for less than $50.
Via
The Motley Fool
Sandoz Pushes Product Launch Plans As Novartis Shareholders Approve The Spin-Off
September 15, 2023
At an Extraordinary General Meeting, Novartis AG's (NYSE: NVS) shareholders
Via
Benzinga
The 3 Most Undervalued Dow Stocks to Buy in September 2023
September 15, 2023
These undervalued Dow stocks have multiple, strong and positive catalysts and are poised to deliver strong returns for investors.
Via
InvestorPlace
Topics
Stocks
Exposures
US Equities
Lawsuit Against Dummy Pills For Allergy, Cold: Johnson & Johnson And Procter & Gamble Face Allegations
September 14, 2023
In a recent lawsuit, Johnson & Johnson (NYSE: JNJ) and Procter & Gamble Co (NYSE: PG) are facing allegations of misleading consumers regarding decongestant cold medicines conta
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
3 Blue-Chip Stocks to Watch in the ‘Green Zone’
September 14, 2023
Now may be the time to take a look at these three blue-chips, as each one is currently in the "Green Zone stocks" category.
Via
InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
September 14, 2023
Via
Benzinga
3 Warren Buffett Stocks That Are Near Their 52-Week Lows
September 14, 2023
Should you consider loading up on these stocks?
Via
The Motley Fool
Buy the Dip: 3 Healthcare Stocks to Snag Now for Supercharged Gains
September 13, 2023
Unearth the three best healthcare stocks to buy that are poised for long-term growth ahead for savvy investors.
Via
InvestorPlace
Here's My Top Growth Stock to Buy in 2023
September 13, 2023
The growth train is leaving the station and you don't want to miss it. Find out why this stock remains a strong buy even after doubling in 2023.
Via
The Motley Fool
NY Consulting Firm Predicts Psychedelic Drugs Market Will Generate Over $12B In Next 12 Years
September 12, 2023
NY-based strategic consulting firm Research Nester launched global market research for psychedelic substances with projections until 2035.
Via
Benzinga
FDA Panel Says Popular OTC Cold, Allergy Medicine Might Be Useless - Stocks To Watch
September 12, 2023
According to FDA panel experts who reviewed the latest research on the long-questioned phenylephrine, a drug ingredient used in several leading decongestants used by millions of Americans looking for...
Via
Benzinga
Exposures
Product Safety
AstraZeneca's Tagrisso-Chemo Combo Data In Lung Cancer Sets High Bar For Johnson & Johnson's Cancer Drug: Analyst
September 11, 2023
On Sunday night, AstraZeneca Plc (NASDAQ: AZN) presented the Phase 3 FLAURA2 results evaluating Tagrisso plus chemotherapy versus Tagrisso monotherapy as first-line treatment for patients
Via
Benzinga
AI Integration In Biotech & Pharma: Companies Positioned To Benefit
September 11, 2023
The convergence of artificial intelligence (AI) with the biotech and pharmaceutical sectors is ushering in a new era of innovation. AI is catalyzing transformations from drug discovery to patient care....
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Another Arthritis Blockbuster Drug Faces Generic Competition: Novartis' Sandoz Inks Pact With Samsung Bioepis
September 11, 2023
Sandoz, a generic and biosimilar medicines unit of Novartis AG (NYSE: NVS), has
Via
Benzinga
< Previous
1
2
...
24
25
26
27
28
29
30
31
32
...
99
100
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.